Zilovertamab vedotin for Breast Cancer

Phase 2

Waitlist Available

Research Sponsored by VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to ~30 months

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing a new drug called zilovertamab vedotin for patients with different types of cancers that have not improved with other treatments. The drug works by finding cancer cells and destroying them.

Eligible Conditions

Adenocarcinoma
Breast cancer
Breast Cancer
Non-Small Cell Lung Cancer
Stomach Cancer
Ovarian Cancer
Pancreatic Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to ~30 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to ~30 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to ~30 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Objective Response Rate (ORR)- Blinded Independent Central Review (BICR)

Secondary study objectives

AUC0-168 hr of MMAE-Q2/3W Dosing Schedule: Day 1

AUC0-168hrs of Total Antibody-Q2/3W Dosing Schedule: Day 1

AUC0-168hrs of Zilovertamab Vedotin -Q2/3W Dosing Schedule: Day 1

+23 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Zilovertamab VedotinExperimental Treatment1 Intervention

Participants will receive intravenous (IV) zilovertamab vedotin 2.5 mg/kg on Day 1 of each repeated 21-day cycle (Q1/3W) or 1.75 mg/kg on Day 1 and Day 8 of each 21-day cycle (Q2/3W). Treatment will continue until progressive disease or discontinuation

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Zilovertamab vedotin

2019

Completed Phase 1

~100

Do I qualify?Apply below to find out